secwatch.observer — SEC 8-K summary
======================================

Issuer:     Unity Biotechnology, Inc. (—)
CIK:        0001463361
Form:       8-K
Filed at:   2024-03-20T23:59:59+00:00
Accession:  0000950170-24-034175
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 4.02
LLM model:  deepseek-v4-flash:cloud@v2

Unity Biotechnology restates financials for warrant misclassification; net loss overstated by $15.5M in 2022
--------------------------------------------------------------------------------

- Audit committee determined warrants issued Aug 2022 should be liabilities, not equity; all affected periods are being restated.
- Previously reported cash, equivalents and marketable securities balances unaffected; cash runway into Q3 2025 unchanged.
- Preliminary cumulative effect: understatement of other income and overstatement of net loss by $15.5M for FY2022, $2.3M for nine months ended Sep 2023.
- Company expects at least one material weakness in internal control over financial reporting; controls deemed ineffective for restated periods.
- Restated financials will be included in 2023 10-K; prior financials for non-reliance periods should no longer be relied upon.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1463361/000095017024034175/0000950170-24-034175-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1463361/000095017024034175/ubx-20240319.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-034175

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer